TY - JOUR
TI - Diabetes and COVID-19; A Bidirectional Interplay
AU - Kazakou, Paraskevi
AU - Lambadiari, Vaia
AU - Ikonomidis, Ignatios and
AU - Kountouri, Aikaterini
AU - Panagopoulos, Georgios
AU - Athanasopoulos,
AU - Stavros
AU - Korompoki, Eleni
AU - Kalomenidis, Ioannis
AU - Dimopoulos,
AU - Meletios A.
AU - Mitrakou, Asimina
JO - FRONTIERS IN ENDOCRINOLOGY
PY - 2022
VL - 13
TODO - null
SP - null
PB - Frontiers Media SA
SN - null
TODO - 10.3389/fendo.2022.780663
TODO - diabetes; COVID-19; endothelial (dys)function; new onset diabetes;
antidiabetic medication
TODO - There seems to be a bidirectional interplay between Diabetes mellitus
(DM) and coronavirus disease 2019 (COVID-19). On the one hand, people
with diabetes are at higher risk of fatal or critical care unit-treated
COVID-19 as well as COVID-19 related health complications compared to
individuals without diabetes. On the other hand, clinical data so far
suggest that the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) may result in metabolic dysregulation and in impaired
glucose homeostasis. In addition, emerging data on new onset DM in
previously infected with SARS-CoV-2 patients, reinforce the hypothesis
of a direct effect of SARS-CoV-2 on glucose metabolism. Attempting to
find the culprit, we currently know that the pancreas and the
endothelium have been found to express Angiotensin-converting enzyme 2
(ACE2) receptors, the main binding site of the virus. To move from bench
to bedside, understanding the effects of COVID-19 on metabolism and
glucose homeostasis is crucial to prevent and manage complications
related to COVID-19 and support recovering patients. In this article we
review the potential underlying pathophysiological mechanisms between
COVID-19 and glucose dysregulation as well as the effects of
antidiabetic treatment in patients with diabetes and COVID-19.
ER -